Skip to content
Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma

Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma

Get the podcast

Sandra Horning Abstract 349 Sandra Horning, Stanford University Medical Center It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therap

The Audio Journal of Oncology
Sandra Horning

Sandra Horning

Abstract 349Sandra Horning, Stanford University Medical CenterIt is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction therapy, brought clear benefits among patients in the study.Click here for all the interviews from ASH 2005

Tags

ashlymphomapatientrituximab

Next in ASH 2005

All 5 interviews

Interview 4 of 5

Targeted Therapies in Multiple Myeloma Treatment Decisions

Targeted Therapies in Multiple Myeloma Treatment Decisions

Vincent Rajkumar Vincent Rajkumar, Divison of Hematology, Mayo Clinic At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkuma

21 December 2005
5 min

Related Episodes

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu

24 Jan 2020
3 min
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev

7 Oct 2019
10 min
Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia

Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia

NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast

19 Dec 2013